18F-ICMT-11 PET imaging can sensitively detect apoptosis, a marker for efficacy in chemotherapy.
Routine clinical use of PET is based on FDG, a glucose analogue. FDG measures viable cell metabolism. However it lacks specificity and FDG imaging often misses less glycolytic/aggressive tumours. Accordingly, there is a need for tracers targeting specific biological processes and molecular pathways.
Effective anticancer therapy induces tumour cell death through apoptosis. Non-invasive monitoring of apoptosis during therapy may provide predictive outcome information and help tailor treatment. Since a majority of oncology therapies induce apoptosis it could be used as an early and specific signal of therapeutic efficacy.
A team at Imperial College London, led by Eric Aboagye, has developed a novel strategy for the detection of treatment efficacy with 18F-ICMT-11 PET in preclinical models of non-small cell lung carcinoma
The team demonstrated 18F-ICMT-11 is a sensitive marker of chemotherapy-induced cell death in preclinical models of lymphoma, breast and colon cancer. They also showed that apoptotic, but not necrotic response of NSCLC to platinum-based therapy is detectable by 18F-ICMT-11, through sub-nanomolar binding to caspase-3.
18F-ICMT-11 PET has been demostrated to be safe in human patients with a dosimetry profile comparable to other 18F PET tracers.
These results establish 18F-ICMT-11 as a good pharmacodynamic marker of apoptosis and biomarker of efficacy even in the absence of tumour shrinkage.
- Sensitive marker of chemotherapy-induced cell death
- Safe and well-tolerated in humans
- Discriminates between apoptosis and necrotic response to platinum-based chemotherapy
Intellectual property information
The technology is protected by a granted patents in the EU and US
Link to published paper(s)
Professor Eric Aboagye – Professor of Cancer Pharmacology and Molecular Imaging, Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre